La vendita allo scoperto per Aston Martin Lagonda Glb dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Aston Martin Lagonda Glb. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Aston Martin Lagonda Glb (OTC:AMGDF) Azioni, Report sulle vendite allo scoperto

Aston Martin Lagonda Global Holdings PLC is a luxury automotive manufacturer. It designs, engineers, and produces sports cars in Warwickshire, United Kingdom, and sells those models through a network of dealers. It is also involved in the servicing of sports cars, all the activities are carried out under the brand name of Aston Martin. The Group has only one operating segment, the automotive segment. The automotive segment includes all activities relating to design, development, manufacture and marketing of vehicles including consulting services; as well as the sale of parts, servicing, and automotive brand activities. Geographically, it has a presence in the United Kingdom, The Americas, the Rest of Europe, the Middle East and Africa, and the Asia Pacific region.

ASTON MARTIN LAGO NEW by Aston Martin Lagonda Global Holdings plc.

Aston Martin Lagonda Global Holdings PLC

<p>Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.75, a high estimate of $8.00, and a low estimate of $6.00. Surpassing the previous average price target of $6.00, the current average has increased by 12.5%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815348_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Geron. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emily Bodnar</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Faisal Khurshid</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Geron. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Geron compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Geron's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Geron's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GERN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Geron analyst ratings.</strong></a></p>
<h2>Get to Know Geron Better</h2>
<p>Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.</p>
<h3>A Deep Dive into Geron's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Geron displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>2941.38%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Geron's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-7639.8%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Geron's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-20.68%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-14.47%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.28</strong>, Geron faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

GERN

Analyst Ratings For Geron

<p>American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate American Electric Power to report an <strong>earnings per share</strong> (EPS) of $1.80.</p>
<p>Anticipation surrounds American Electric Power's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.02% drop in the share price on the subsequent day.</p>
<p>Here's a look at American Electric Power's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.23</td>
<td>1.26</td>
<td>1.26</td>
<td>1.71</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.25</td>
<td>1.27</td>
<td>1.23</td>
<td>1.77</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-0.0%</td>
<td>2.0%</td>
<td>4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815348_0.png" alt="eps graph" /></p>
<h3>Performance of American Electric Power Shares</h3>
<p>Shares of American Electric Power were trading at $98.4 as of November 04. Over the last 52-week period, shares are up 25.91%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on American Electric Power</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding American Electric Power.</p>
<p>The consensus rating for American Electric Power is Outperform, based on 12 analyst ratings. With an average one-year price target of $106.75, there's a potential 8.49% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of PG&amp;E, Exelon and Xcel Energy, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for PG&amp;E, with an average 1-year price target of $23.0, indicating a potential 76.63% downside.</li>
<li>For Exelon, analysts project an Neutral trajectory, with an average 1-year price target of $43.33, indicating a potential 55.97% downside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Xcel Energy, with an average 1-year price target of $69.45, implying a potential 29.42% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for PG&amp;E, Exelon and Xcel Energy, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Electric Power</td>
<td>Outperform</td>
<td>4.73%</td>
<td>$2.86B</td>
<td>1.31%</td>
</tr>
<tr>
<td>PG&amp;E</td>
<td>Buy</td>
<td>13.16%</td>
<td>$2.26B</td>
<td>2.00%</td>
</tr>
<tr>
<td>Exelon</td>
<td>Neutral</td>
<td>2.91%</td>
<td>$2.50B</td>
<td>2.68%</td>
</tr>
<tr>
<td>Xcel Energy</td>
<td>Neutral</td>
<td>-0.49%</td>
<td>$1.86B</td>
<td>3.66%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>American Electric Power ranks highest in revenue growth among its peers. It has the lowest gross profit and return on equity compared to its peers.</p>
<h3>Get to Know American Electric Power Better</h3>
<p>American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 42% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (21%), nuclear (8%), and demand response (2%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.</p>
<h3>Financial Insights: American Electric Power</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining American Electric Power's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>4.73%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> American Electric Power's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>7.43%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.31%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> American Electric Power's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.34%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> American Electric Power's debt-to-equity ratio surpasses industry norms, standing at <strong>1.7</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/AEP/earnings"><strong>To track all earnings releases for American Electric Power visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

Insights Ahead: American Electric Power's Quarterly Earnings

<p>Barclays  analyst Nicholas Campanella   maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Overweight and raises the price target from $137 to $152.</p>


News

Price Target

Barclays Maintains Overweight on Entergy, Raises Price Target to $152

<p>Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) reported quarterly earnings of $0.69 per share which missed the analyst consensus estimate of $0.75 by 8 percent.  The company reported quarterly sales of $44.356 million which missed the analyst consensus estimate of $45.842 million by 3.24 percent.  This is a 81.40 percent increase over sales of $24.452 million the same period last year.</p>


Earnings Misses

SHIP

Seanergy Maritime Hldgs Q3 2024 Adj. EPS $0.69 Misses $0.75 Estimate, Sales $44.356M Miss $45.842M Estimate

Biotech

General

TSBX

Turnstone Biologics Showcases Preclinical Data On Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy For Solid Tumors At SITC 2024, Supporting Clinical Advancement Of TIDAL-01 In Phase 1 Trials

<p>Western Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Western Midstream will report an <strong>earnings per share</strong> (EPS) of $0.83.</p>
<p>Investors in Western Midstream are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.09 in the last quarter, leading to a 1.13% increase in the share price on the following day.</p>
<p>Here's a look at Western Midstream's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.88</td>
<td>0.81</td>
<td></td>
<td>0.65</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.97</td>
<td>1.47</td>
<td>0.74</td>
<td>0.70</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>3.0%</td>
<td>11.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Performance of Western Midstream Shares</h3>
<p>Shares of Western Midstream were trading at $36.81 as of November 01. Over the last 52-week period, shares are up 34.1%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Western Midstream</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Western Midstream.</p>
<p>Analysts have given Western Midstream a total of 6 ratings, with the consensus rating being Neutral. The average one-year price target is $40.0, indicating a potential 8.67% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Plains All American, DT Midstream and Antero Midstream, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Plains All American is favoring an Neutral trajectory, with an average 1-year price target of $19.0, suggesting a potential 48.38% downside.</li>
<li>DT Midstream is maintaining an Neutral status according to analysts, with an average 1-year price target of $88.14, indicating a potential 139.45% upside.</li>
<li>The prevailing sentiment among analysts is an Underperform trajectory for Antero Midstream, with an average 1-year price target of $16.0, implying a potential 56.53% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Plains All American, DT Midstream and Antero Midstream are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Western Midstream</td>
<td>Neutral</td>
<td>22.67%</td>
<td>$688.19M</td>
<td>11.34%</td>
</tr>
<tr>
<td>Plains All American</td>
<td>Neutral</td>
<td>11.47%</td>
<td>$468M</td>
<td>1.75%</td>
</tr>
<tr>
<td>DT Midstream</td>
<td>Neutral</td>
<td>5.98%</td>
<td>$195M</td>
<td>2.09%</td>
</tr>
<tr>
<td>Antero Midstream</td>
<td>Underperform</td>
<td>2.14%</td>
<td>$185.61M</td>
<td>4.68%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Western Midstream ranks in the top quartile for Revenue Growth and Gross Profit among its peers. However, it ranks in the bottom quartile for Return on Equity.</p>
<h3>Unveiling the Story Behind Western Midstream</h3>
<p>Western Midstream Partners LP is a US-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.</p>
<h3>Western Midstream: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Western Midstream's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>22.67%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Western Midstream's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>40.84%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Western Midstream's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>11.34%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Western Midstream's ROA excels beyond industry benchmarks, reaching <strong>3.03%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Western Midstream's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.18</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/WES/earnings"><strong>To track all earnings releases for Western Midstream visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Western Midstream's Earnings: A Preview

<p>Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) in the last three months.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $495.09, a high estimate of $600.00, and a low estimate of $425.00. Witnessing a positive shift, the current average has risen by 1.47% from the previous average price target of $487.90.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815318_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Vertex Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$476.00</td>
<td>$473.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$540.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$562.00</td>
<td>$477.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$480.00</td>
<td>-</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$541.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$437.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$425.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$474.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$431.00</td>
<td>$431.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Vertex Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Vertex Pharmaceuticals analyst ratings.</strong></a></p>
<h2>About Vertex Pharmaceuticals</h2>
<p>Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.</p>
<h3>Vertex Pharmaceuticals: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Vertex Pharmaceuticals showcased positive performance, achieving a revenue growth rate of <strong>6.11%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Vertex Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-135.83%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-21.57%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vertex Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-16.32%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.06</strong>, Vertex Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VRTX

Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts

WIIM

Dr. Reddy's Laboratories shares are trading higher after the company reported a year-over-year increase in Q2 sales results.

<ul>
<li><i>Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical models of melanoma</i></li>
<li><i>CAN-3110's activity is designed to be conditional to the expression of Nestin in cancer cells and is associated with dual activity for oncolysis and immune activation</i></li>
<li><i>Findings support potential indication expansion for CAN-3110 beyond high-grade glioma into melanoma, another Nestin-expressing solid tumo</i></li>
</ul>


Events

CADL

Candel Therapeutics To Present Preclinical Results For CAN-3110 In Melanoma At SITC Annual Meeting

<p>Analysts' ratings for WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for WESCO Intl, revealing an average target of $210.57, a high estimate of $225.00, and a low estimate of $187.00. Witnessing a positive shift, the current average has risen by 9.02% from the previous average price target of $193.14.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815296_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive WESCO Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$199.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Christopher Glynn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Ken Newman</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$223.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$187.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$210.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WESCO Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of WESCO Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into WESCO Intl's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WCC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on WESCO Intl analyst ratings.</strong></a></p>
<h2>Delving into WESCO Intl's Background</h2>
<p>Wesco International is an industrial distributor that has three reportable segments, electrical and electronic solutions, communications and security solutions, and utility and broadband solutions. The company offers more than 1.5 million products to its 140,000 active customers through a distribution network of 800 branches, warehouses, and sales offices, including 43 distribution centers. Wesco generates approximately 74% of its sales in the United States, but it has a global reach, with operations in 50 other countries.</p>
<h3>Understanding the Numbers: WESCO Intl's Finances</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, WESCO Intl faced challenges, resulting in a decline of approximately <strong>-2.75%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> WESCO Intl's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>3.46%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> WESCO Intl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>3.84%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.25%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> WESCO Intl's debt-to-equity ratio is below the industry average at <strong>1.12</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 7 Analyst Ratings Have To Say About WESCO Intl

<p>RenaissanceRe Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect RenaissanceRe Holdings to report an <strong>earnings per share</strong> (EPS) of $7.75.</p>
<p>The announcement from RenaissanceRe Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $1.77 in the last quarter, leading to a 2.27% drop in the share price on the following day.</p>
<p>Here's a look at RenaissanceRe Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>10.64</td>
<td>9.41</td>
<td>8.10</td>
<td>6.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>12.41</td>
<td>12.18</td>
<td>11.77</td>
<td>8.33</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-0.0%</td>
<td>6.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815288_0.png" alt="eps graph" /></p>
<h3>RenaissanceRe Holdings Share Price Analysis</h3>
<p>Shares of RenaissanceRe Holdings were trading at $266.49 as of November 04. Over the last 52-week period, shares are up 29.48%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RNR/earnings"><strong>To track all earnings releases for RenaissanceRe Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of RenaissanceRe Holdings's Earnings

CRUS

Cirrus Logic shares are trading lower following Q2 earnings.

<ul>
<li>New analyses from the IMerge clinical trial suggest that imetelstat demonstrates clinical activity in patients with lower-risk MDS with transfusion-dependent anemia regardless of prior therapy</li>
<li>Early safety results from the dose escalation phase of the Phase 1 IMproveMF study suggest potential for the tolerability of combination therapy with imetelstat and ruxolitinib in a frontline myelofibrosis patient population</li>
</ul>
<p>&nbsp;</p>
<p>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the publication of abstracts containing new data highlighting the potential of RYTELO&#x2122; (imetelstat), a first-in-class telomerase inhibitor, in myeloid hematologic malignancies. Six abstracts have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting taking place from December 7-10, 2024, in San Diego, California and virtually.</p>


Geron Announces New Data To Be Presented Highlighting The Potential Of RYTELO In Myeloid Hematologic Malignancies At Upcoming ASH Annual Meeting

<p>Barclays  analyst Alex Scott   maintains Corebridge Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRBG#NYSE">CRBG</a>) with a Equal-Weight and raises the price target from $34 to $36.</p>


CRBG

Barclays Maintains Equal-Weight on Corebridge Financial, Raises Price Target to $36

<p>MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has outperformed the market over the past 20 years by 11.02% on an annualized basis producing an average annual return of 19.17%. Currently, MicroStrategy has a market capitalization of $46.08 billion. </p>
<p><strong>Buying $100 In MSTR:</strong> If an investor had bought $100 of MSTR stock 20 years ago, it would be worth <strong>$3,430.62</strong> today based on a price of $227.39 for MSTR at the time of writing.</p>
<h3>MicroStrategy's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815254_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

MSTR

$100 Invested In MicroStrategy 20 Years Ago Would Be Worth This Much Today

<p>Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 4.08% on an annualized basis producing an average annual return of 14.89%. Currently, Zoetis has a market capitalization of $79.87 billion. </p>
<p><strong>Buying $1000 In ZTS:</strong> If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth <strong>$4,362.05</strong> today based on a price of $176.29 for ZTS at the time of writing.</p>
<h3>Zoetis's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815248_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,400 Today

Tempus AI shares are trading lower after the company reported mixed Q3 financial results. Also, the company announced it entered into an agreement to acquire Ambry Genetics.

<p>Barclays  analyst Tom O'Malley   maintains Cirrus Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) with a Equal-Weight and lowers the price target from $120 to $105.</p>


Barclays Maintains Equal-Weight on Cirrus Logic, Lowers Price Target to $105

Fabrinet shares are trading lower. The company reported Q1 financial results.

<p>With election day underway, prediction markets Polymarket and Kalshi are showing divergent odds for <strong>Kamala Harris</strong> and <strong>Donald Trump</strong> as major politics traders have placed their bets <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">on the Vice President</a>.</p>
<p><strong>What Happened:</strong> Kamala Harris&#8217;s odds of winning the presidency stand at 41% on Kalshi, compared to 38.4% on Polymarket at the time of writing. The spread between the two platforms was as big as 6% in the early morning U.S. Eastern time. Kalshi <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41583301/kalshi-ceo-tarek-mansour-on-the-growing-election-betting-market-a-coin-flip-with-a-bias">has a license</a> from the Commodity Futures Trading Commission (CFTC) to list election-related trading contracts.</p>
<p>The top three traders on Polymarket have all sided with the Vice President to win the election.</p>
<ul>
<li>Veteran trader Domer has <a href="https://polymarket.com/profile/0x9d84ce0306f8551e02efef1680475fc0f1dc1344">wagered</a> $224,344 on Harris winning the electoral college, $147,766 on a Democrat taking both the popular vote and Presidency and $164,884 on a Democrat winning the state of Pennsylvania. In a post on <strong>X</strong>, the all-time leading trader on the platform <a href="https://x.com/Domahhhh/status/1853086999873196202">cited</a> his estimate of Kamala Harris&#8217;s chances to win the election around 55-60%.</li>
<li>The second trader on Polymarket&#8217;s all-time ranking, Rueben, <a href="https://polymarket.com/profile/0x3cf3e8d5427aed066a7a5926980600f6c3cf87b3">bet</a> over $300,000 on the Vice President to win the popular vote, the electoral college and the Democratic Party to win the Presidency and the House but lose control of the Senate. However, the trader also has a roughly $50,000 stake on the GOP to win the electoral college but lose the popular vote., with a total profit of $1.6 million <a href="https://polymarket.com/profile/0x3cf3e8d5427aed066a7a5926980600f6c3cf87b3">recorded</a> in his portfolio.</li>
<li>Third-placed trader YatSen <a href="https://polymarket.com/profile/0x5bffcf561bcae83af680ad600cb99f1184d6ffbe">bet</a> $172,810 on a Democratic win in the popular vote and presidency, and $57,622 on Harris. The trader also has over $120,000 staked on an electoral college/popular vote split where Trump wins the presidency.</li>
</ul>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><strong>What&#8217;s Next</strong>: The influence of prediction markets is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41720318/bitcoin-on-the-evening-of-the-election-heres-how-it-performed-in-2012-2016-and-2020">Bitcoin On The Evening Of The Election—Here&#8217;s How It Performed In 2012, 2016 And 2020</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Kamala Harris Backed By Polymarket's Top 3 All-Time Traders, But Two Of Them Have Hedged Their Bets

Aston Martin Lagonda Global Holdings plc (AMGDF) Q4 2023 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The market is quickly realizing electric vehicles just might not be the future. Suddenly, investors are shunning this once hot sector, a grim reality for EV upstarts like <strong>Lucid Group</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lcid-stock-quote/"><strong>LCID</strong></a></span>), which isn&rsquo;t finding traction.&nbsp;</p>



<p>The deceleration in <a href="https://investorplace.com/2023/11/lucid-investors-dont-be-fooled-this-news-is-not-a-reason-to-buy-lcid-stock/">EV sales growth</a> is accelerating. Manufacturers are leaving the market or scaling back expectations. <strong>Apple</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/aapl-stock-quote/"><strong>AAPL</strong></a></span>) just abandoned its EV plans. </p>



<p><strong>Volvo</strong> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/vlvly-stock-quote/"><strong>VLVLY</strong></a></span>) said it won&rsquo;t dump any more money into <strong>Polestar</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/psny-stock-quote/"><strong>PSNY</strong></a></span>) and luxury automaker <strong>Aston Martin</strong> (OTCMKTS:<span><a href="https://investorplace.com/stock-quotes/amgdf-stock-quote/"><strong>AMGDF</strong></a></span>) delayed introducing its own high-end EV. </p>



<p>Chairman Lawrence Stroll says &ldquo;The consumer demand (for EVs), certainly at an Aston Martin price point, is not what we thought it was going to be two years ago.&rdquo;</p>



<p>Even if Lucid&rsquo;s luxury EV starts at a lower price point than the upscale Aston Martin, it is an ill omen and investors should steer clear. Here&rsquo;s why LCID stock doesn&rsquo;t belong in your portfolio.</p>



<h2>A Closer Look at LCID Stock</h2>



<p>Lucid is spiraling down. The only reason the carmaker&rsquo;s situation doesn&rsquo;t look more dire is because Saudi Arabia&rsquo;s <strong>Public Investment Fund</strong>, owns a 60% majority stake in the company. </p>



<p>It is keeping the motor company afloat to <a href="https://investorplace.com/2024/01/lcid-stock-forecast-is-2024-the-year-lucid-breaks-through/">jumpstart the electric vehicle industry</a> in the country. Absent the sovereign wealth fund&rsquo;s massive $5.4 billion cash injections Lucid would likely be in its death throes. It is almost there already though it received $1.8 billion alone in the third quarter.</p>



<p>The EV stock is living on borrowed time. On the one hand, it undeniably has a quality product that is a technological marvel. In almost any other time, it would be an unqualified success. But we&rsquo;re not in those times. Instead, we have an EV market shunning high-prices, a difficult environment for a luxury carmaker.</p>



<p>Lucid estimates it will productive 9,000 vehicles in 2024 but investors know there is a good chance that will be revised downward. Management even <a href="https://ir.lucidmotors.com/static-files/9738aa79-10bb-4508-9053-8d5e728bf004">acknowledges the likelihood</a> based on demand. </p>



<p>It says it will &ldquo;prudently manage and adjust production to meet sales and delivery needs.&rdquo; As there will be no sudden burst of buying, that can only mean downward revisions. That will weigh on Lucid&rsquo;s finances.</p>



<h2>Hit or Miss Goals</h2>



<p>Yet Lucid is not going bankrupt. Lucid has sufficient liquidity to survive through at least 2025, and Saudi Arabia is committed to buying 50,000 vehicles. So if Lucid can keep production going it will be able to at least get rid of its inventory to the Saudi government.</p>



<p>That hardly seems an investment worthy opportunity, though. A company living on raising money to survive via the debt and equity markets is not necessarily a healthy business. </p>



<p>Revenue is sliding and operating losses are mounting. It reported a <a href="https://www.sec.gov/Archives/edgar/data/1811210/000162828024005904/q423ex991k.htm">$3.1 billion loss</a> in 2023 and fired hundreds of factory workers to contain costs. Lucid continues to burn through substantial amounts of cash every quarter.</p>



<p>Management also keeps missing production targets. The 8,400 vehicles it delivered last year was well below the original 10,000 goal it had set. That&rsquo;s why investors should be skeptical of the new goals Lucid laid out, despite the company insisting it worked out all the kinks in its production line.</p>



<h2>Better Opportunities Available</h2>



<p>Investors buying in now even with the stock down more than 95% from its all-time high are at risk of losing it all. There is no logical reason for Lucid to have such a rich valuation. </p>



<p>The company cut prices on its flagship Air to under $70,000 to spur sales it will make financial ends meet more difficult. It will need to dilute shareholders further to raise more cash. At some point even Saudi Arabia might turn off the spigot.</p>



<p>Buyers don&rsquo;t want all-electric cars. They are hedging their bets, <a href="https://investorplace.com/2024/02/this-is-the-one-and-only-ev-stock-to-buy-today-and-2-to-sell/">buying hybrid vehicles</a> instead. Lucid Group produces an excellent product, but its business is in trouble. </p>



<p>There are much better opportunities to bet on instead of buying LCID stock. The risk is too great and will offset any potential reward.</p>



<p><em>On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a></em></p>
<div><p>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/03/lcid-stock-analysis-too-much-risk-not-enough-reward/">LCID Stock Analysis: Too Much Risk, Not Enough Reward</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Comments

Aston Martin Lagonda Glb

Vendite allo scoperto

Aston Martin Lagonda Glb (OTC:AMGDF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO